CD7 Nanobody for Targeted Therapy and Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current research lacks specific nanobodies directed against human CD7 epitopes, which are essential for targeted delivery of therapeutic agents to CD7-positive cells, such as leukemia and lymphoma cells, due to the difficulty of conventional antibodies in penetrating tissues and being expressed in prokaryotic systems.
Innovation Solution
Development of a human CD7 nanobody with a VHH chain comprising specific framework and complementarity determining regions, encoded by a DNA molecule, for use in detection reagents, immunofluorescence assays, and as part of immunoconjugates for targeted therapy, allowing efficient expression in E. coli and specific binding to CD7 molecules.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-chain antibodies (scFv) are used for targeting CD7 molecules, then therapeutic delivery to leukemia and lymphoma cells can be achieved, but the molecular weight is relatively large (30 kDa) which makes it difficult to invade into tissues and cells
Solution Approach 1:
The patent divides the conventional antibody structure into a single-domain nanobody (VHH) that retains only the essential antigen-binding function. This segmentation reduces the molecular weight from 30 kDa (scFv) to approximately 15 kDa (nanobody), enabling better tissue penetration while maintaining therapeutic delivery capability to CD7-positive cells
Solution Approach 2:
The patent extracts the variable heavy chain domain (VHH) from the complete antibody structure, removing unnecessary components (light chains, constant regions) that contribute to molecular weight but are not essential for antigen binding. This extracted VHH domain maintains the ability to bind CD7 molecules while achieving reduced size for improved tissue invasion
2Reliability
If single-chain antibodies (scFv) are used for CD7 targeting, then immunotoxin conjugation can be performed, but expression in prokaryotic systems is difficult in soluble form
Solution Approach 1:
The patent changes the structural parameters of the antibody by using a camelid-derived single-domain VHH structure instead of conventional scFv. This structural parameter change (single domain vs. two-chain structure) fundamentally improves prokaryotic expression characteristics, enabling high-level soluble expression in E. coli systems while maintaining immunotoxin conjugation capability
3Reliability
If conventional antibodies are used for disease treatment, then high affinity binding to CD7 can be achieved, but the molecular weight prevents easy penetration into tissues
Solution Approach 1:
The patent extracts only the variable heavy chain domain (VHH) from complete antibodies, removing constant regions and light chains. This extracted domain maintains high affinity binding to CD7 molecules through its CDR regions while reducing molecular weight to approximately 15 kDa, enabling easy tissue penetration
4Ease of manufacture
If nanobodies are used instead of conventional antibodies, then expression in prokaryotic systems is easy and soluble, but specific nanobodies against human CD7 epitopes were previously unavailable
Solution Approach 1:
The patent performs preliminary immunization of camels with human CD7-positive cell lines (Jurkat, CEM) to generate nanobodies with predetermined specificity to human CD7 epitopes. This preliminary action ensures that the resulting nanobodies are both specific to human CD7 and capable of efficient prokaryotic expression
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CD7 nanobody enables efficient targeting and binding to CD7-positive cells, facilitating targeted therapy and detection, with improved expression and stability, and can be used to deliver toxins or siRNAs, demonstrating high specificity and affinity.
Implementation Method 1
a nanobody against human CD7 molecule... specific binding to CD7 molecules
Implementation Method 2
Nanobodies can easily penetrate the tissue due to the small molecular weight to reach the site which is difficult to be reached by conventional antibodies
Implementation Method 3
when it binds to its antibody, it starts endocytosis immediately
Data Source
AI summary
Provided is a nanometer antibody for human CD7 molecule and an encoding DNA sequence thereof. The nanometer antibody can be efficiently expressed in Escherichia coli, and can be used for preparing an agent for the detection of CD7 molecule and targeted therapy.